2.30
2.30 (0%)
As of Apr 17, 2025
Mereo Biopharma Group Plc [MREO]
Source:
Company Overview
Mereo Biopharma Group Plc is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease product candidates are setrusumab for the treatment of OI and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
| Country | United Kingdom |
| Headquarters | london, united kingdom |
| Phone Number | 44-333-023-7300 |
| Industry | manufacturing |
| CEO | Denise Scots-Knight |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-47.4 |
| Net Income | $-43.3 |
| Net Cash | $12.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -60.5% |
| Profit as % of Stockholder Equity | -70.9% |
Management Effectiveness
| Return on Equity | -70.9% |
| Return on Assets | -56.6% |
| Turnover Ratio | |
| EBITA | $-47.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $76.4 |
| Total Liabilities | $15.4 |
| Operating Cash Flow | $-32.8 |
| Investing Cash Flow | $-0.7 |
| Financing Cash Flow | $46.1 |
